- Home
- TMQ vs NGNE Comparison
TMQ vs NGNE Comparison
Compare TMQ & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- NGNE
- Stock Information
- Founded
- TMQ 2004
- NGNE 2003
- Country
- TMQ Canada
- NGNE United States
- Employees
- TMQ N/A
- NGNE N/A
- Industry
- TMQ Precious Metals
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- TMQ Basic Materials
- NGNE Health Care
- Exchange
- TMQ Nasdaq
- NGNE Nasdaq
- Market Cap
- TMQ 211.9M
- NGNE 251.9M
- IPO Year
- TMQ N/A
- NGNE N/A
- Fundamental
- Price
- TMQ $1.39
- NGNE $17.86
- Analyst Decision
- TMQ
- NGNE Strong Buy
- Analyst Count
- TMQ 0
- NGNE 7
- Target Price
- TMQ N/A
- NGNE $41.86
- AVG Volume (30 Days)
- TMQ 343.8K
- NGNE 186.5K
- Earning Date
- TMQ 07-09-2025
- NGNE 08-08-2025
- Dividend Yield
- TMQ N/A
- NGNE N/A
- EPS Growth
- TMQ N/A
- NGNE N/A
- EPS
- TMQ N/A
- NGNE N/A
- Revenue
- TMQ N/A
- NGNE $925,000.00
- Revenue This Year
- TMQ N/A
- NGNE N/A
- Revenue Next Year
- TMQ N/A
- NGNE N/A
- P/E Ratio
- TMQ N/A
- NGNE N/A
- Revenue Growth
- TMQ N/A
- NGNE N/A
- 52 Week Low
- TMQ $0.43
- NGNE $6.88
- 52 Week High
- TMQ $2.09
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- TMQ 56.60
- NGNE 48.91
- Support Level
- TMQ $1.22
- NGNE $18.22
- Resistance Level
- TMQ $1.44
- NGNE $21.43
- Average True Range (ATR)
- TMQ 0.07
- NGNE 2.15
- MACD
- TMQ 0.02
- NGNE -0.45
- Stochastic Oscillator
- TMQ 86.60
- NGNE 19.98
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.